Nippon Chemiphar : First Quarter Business Summary FY2021. (pdf, 280KB)

（TSE 4539）

FY2021 First Quarter Business Summary

(Year Ending March 31, 2022)

Sales, Income

										(¥mn)
			FY2020				FY2021
		1Q	Distrib.	Full Year	1Q	Distrib.	YOY	Full Year	Progress
		Amount	(%)	Amount	Amount	(%)	(%)		(Forecast)	Rate (%)
Net sales	7,196	100.0	31,541	7,575	100.0	―	31,000	24.4
Pharmaceuticals	7,146	99.3	30,423	7,377	97.4	―	―	―
Others		49	0.7	1,117	197	2.6	―		―	―
Cost of sales		4,640	64.5	20,097	5,529	73.0	―		―	―
SG&A expenses	2,589	36.0	10,879	2,071	27.3	―	―	―
R&D expenses		477	6.6	1,998	620	8.2	―		2,400	25.9
Operating income/loss	(32)	―	564	(26)	―	―	350	―
Income/Loss before income
taxes and minority interests	(12)	―	713	15	0.2	―	―	―
Net income/loss attributable to
owners of the parent		19	0.3	495	(13)	―	―		80	―

Note:

We applied "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021.

Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated.

1

Pharmaceutical Sales

Generics, Proprietary Products and New Drugs								(¥mn)
				FY2020				FY2021
			1Q	Distrib.	Full Year	1Q	Distrib.	YOY	Full Year	Progress
			Amount	(%)	Amount	Amount	(%)	(%)			(Forecast)	Rate (%)
Total		6,388	100.0	27,322	6,569	100.0	―		26,550	24.7
Generics	6,109	95.6	25,532	6,111	93.0	―		24,700	24.7
To medical institutions	5,860		24,531	5,817		―		23,600	24.6
To other makers*	248		1,000	294		―		1,100	26.8
Proprietary products	279	4.4	1,790	457	7.0	―		1,850	24.7
	Uralyt		184		730	156		―			580	26.9
	Others	94		1,059	301		―		1,270	23.8
Chemiphar, ODM Generics											(¥mn)
				FY2020				FY2021
			1Q	Distrib.	Full Year	1Q	Distrib.	YOY	Full Year	Progress
			Amount	(%)	Amount	Amount	(%)	(%)			(Forecast)	Rate (%)
Total		6,506	100.0	26,696	6,337	100.0	―			25,410	24.9
Generics		6,109	93.9	25,532	6,111	96.4	―			24,700	24.7
Generics (ODM)		397	6.1	1,164	226	3.6	―		710	31.8

* Includes exports.

Note:

We applied "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021.

Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated.

2

Sales Distribution

By Launch Year						(¥mn)
		FY2020		FY2021
		1Q	Distrib.	1Q	Distrib.	YOY
		Amount	(%)	Amount	(%)	(%)
FY2014 and before		4,993	81.7	4,715	77.2	―
FY2015		251	4.1	272	4.5	―
FY2016		137	2.3	137	2.2	―
FY2017		336	5.5	368	6.0	―
FY2018		216	3.5	189	3.1	―
FY2019		29	0.5	32	0.5	―
FY2020	143	2.3	337	5.5	―
FY2021		―	―	59	1.0	―
Total	6,109	100.0	6,111	100.0	―

By Main Therapeutic Categories			(%)
		FY2020		FY2021
		1Q		1Q
Cardiovascular and respiratory drugs		33.1		28.3
Digestive organ drugs		16.1		15.6
Agents affecting metabolism		16.0		15.4
Drugs for nervous system, sensory organs		11.8		13.0
Antibiotics and chemotherapeutic drugs		4.3		6.5
Antineoplastic agents		3.3		2.5
Others		17.4		18.7

Note:

We applied "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021. Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated.

3

Balance Sheet, per Share Information

Balance Sheet Data										(¥mn)
			March 31, 2021			June 30, 2021
			Amount			Amount	Change
Total assets		47,124			48,127	1,002
Net assets	18,014	17,907	(107)
Owned capital	17,997	17,890	(107)
Capital-to-asset ratio (%)		38.2			37.2	(1.0)
Current assets		30,446			31,605	1,159
Current liabilities	14,102	14,386	283
Current ratio (x)	2.16	2.20	0.04
Per Share Information													(¥)
			FY2020				FY2021
			1Q			Full Year		1Q	YOY		Full Year
			Amount			Amount		Amount		(Forecast)
Earnings per share	5.45			137.75	(3.66)	―	22.25
														Full Year
			June 30, 2020	March 31, 2021		June 30, 2021			(Forecast)
Book value per share	4,811.70			5,006.49		4,976.70	165.00		―
Dividends per share			―			50.00			―	―		50.00
Dividend payout ratio (%)			―	36.3			―	―	224.7
Note:
We applied "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021.
Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated.

4